NEW YORK (GenomeWeb News) – Rosetta Genomics has received a clinical laboratory permit from the New York State Department of Health allowing the firm to offer its microRNA-based tests to physicians and patients in the state.
The firm currently sells three tests — the miRview meso, miRview mets, and miRview squamous — that are run at its own Philadelphia-based CAP-accredited, CLIA-certified lab.
The miRview meso test differentiates lung cancer from mesothelioma; miRview mets is designed to determine the source of cancers of unknown primary origin; and miRview squamous is designed to differentiate squamous from non-squamous non-small cell lung cancer.
Rehovot, Israel-based Rosetta said that it also is working with the NYS DOH to gain approval for its second-generation versions of the tests.
Rosetta Genomics President and CEO Kenneth Berlin noted that the firm's tests are now available to residents of all 50 states in the US.